A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• 18 through 64 years of age diagnosed with RRMS, who can walk without aid or rest for at least 200 meters (approximately 1/10 of a mile).

• Women who can become pregnant must use birth control.

Exclusion Criteria:

• Have had a live vaccination within 12 weeks before randomization, or intend to have a live vaccination during the course of the study.

• Have had had recent surgery or are scheduled to have surgery during the study.

• Are immunocompromised or have evidence of active infection [such as hepatitis, tuberculosis or, human immunodeficiency virus (HIV)].

• Have been on certain drugs that are being studied for RRMS or have recently received prescription drugs to treat RRMS.

• Have had a recent serious infection.

• Have serious or uncontrolled illnesses other than RRMS.

• Have clinically significant blood test values.

• Have multiple or severe drug allergies.

• Have contraindications for MRI "scanning" or claustrophobia (fear of an enclosed space) that cannot be managed.